Cargando…

A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease

BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hattori, Nobutaka, Kitabayashi, Hiroki, Kanda, Tomoyuki, Nomura, Takanobu, Toyama, Keizo, Mori, Akihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496465/
https://www.ncbi.nlm.nih.gov/pubmed/32501582
http://dx.doi.org/10.1002/mds.28095
_version_ 1783583103064735744
author Hattori, Nobutaka
Kitabayashi, Hiroki
Kanda, Tomoyuki
Nomura, Takanobu
Toyama, Keizo
Mori, Akihisa
author_facet Hattori, Nobutaka
Kitabayashi, Hiroki
Kanda, Tomoyuki
Nomura, Takanobu
Toyama, Keizo
Mori, Akihisa
author_sort Hattori, Nobutaka
collection PubMed
description BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHODS: We performed a pooled analysis of data from two identical phase 2b and 3 Japanese studies of istradefylline. Logistic regression models were used to assess the association of 12 patient characteristics with favorable outcomes. RESULTS: Off time reduction and increased good on time with istradefylline provided a significantly favorable response in patients aged ≥65 years. Off time reduction was more favorable in patients with ≥8‐hour daily off time at baseline. Improvement in UPDRS Part III was favorable in patients with UPDRS Part III baseline score ≥ 20. CONCLUSIONS: Several patient factors influenced the effect of istradefylline on motor fluctuations, motor function, activities of daily living, and clinical impression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
format Online
Article
Text
id pubmed-7496465
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-74964652020-09-25 A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease Hattori, Nobutaka Kitabayashi, Hiroki Kanda, Tomoyuki Nomura, Takanobu Toyama, Keizo Mori, Akihisa Mov Disord Regular Issue Articles BACKGROUND: Characterization of patient factors associated with istradefylline efficacy may facilitate personally optimized treatment. OBJECTIVES: We aimed to examine which patient factors are associated with favorable istradefylline treatment outcomes in PD patients with motor complications. METHODS: We performed a pooled analysis of data from two identical phase 2b and 3 Japanese studies of istradefylline. Logistic regression models were used to assess the association of 12 patient characteristics with favorable outcomes. RESULTS: Off time reduction and increased good on time with istradefylline provided a significantly favorable response in patients aged ≥65 years. Off time reduction was more favorable in patients with ≥8‐hour daily off time at baseline. Improvement in UPDRS Part III was favorable in patients with UPDRS Part III baseline score ≥ 20. CONCLUSIONS: Several patient factors influenced the effect of istradefylline on motor fluctuations, motor function, activities of daily living, and clinical impression. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. John Wiley & Sons, Inc. 2020-06-05 2020-08 /pmc/articles/PMC7496465/ /pubmed/32501582 http://dx.doi.org/10.1002/mds.28095 Text en © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Regular Issue Articles
Hattori, Nobutaka
Kitabayashi, Hiroki
Kanda, Tomoyuki
Nomura, Takanobu
Toyama, Keizo
Mori, Akihisa
A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title_full A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title_fullStr A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title_full_unstemmed A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title_short A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
title_sort pooled analysis from phase 2b and 3 studies in japan of istradefylline in parkinson's disease
topic Regular Issue Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496465/
https://www.ncbi.nlm.nih.gov/pubmed/32501582
http://dx.doi.org/10.1002/mds.28095
work_keys_str_mv AT hattorinobutaka apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT kitabayashihiroki apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT kandatomoyuki apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT nomuratakanobu apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT toyamakeizo apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT moriakihisa apooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT hattorinobutaka pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT kitabayashihiroki pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT kandatomoyuki pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT nomuratakanobu pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT toyamakeizo pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease
AT moriakihisa pooledanalysisfromphase2band3studiesinjapanofistradefyllineinparkinsonsdisease